The Finnish developers of a new and tiny silicon-based timer circuit are looking for partners with application-specific engineering and marketing expertise to take the product further.

The first protein drug extracted from the milk of a genetically modified animal has finally received European approval.

The TeGenero drug trial is complete, and an ongoing study is examing whether trial requirements should be changed. But, asks Nuala Moran, should the trial ever have been approved?

Fujeribio Diagnostics, Inc., based in Japan, has bought Swedish CanAg Diagnostics, merging two leading biotechnology companies in cancer diagnosis.

Microsoft Corp. is spinning out some of its software technology to two small European tech ventures, as part of a program to speed development of innovations from its labs.

A team of researchers at ORNL has come up with the concept of nanofermentation, and, it seems, plans to use this as a trademark.

Europabio thinks that Europe is doing a poor job when it comes to investing in biotechnology.

On May 26, the US Patent Office issued a preliminary ruling on another long-running patent fight. This battle differs from other high-profile clashes as the challenger is taking on not a big corporate entity, but a broad community of IT researchers and academics.

Researchers at four European universities are collaborating to develop software that will help encourage the take-up of so called pervasive computing.

European biotech is a hot topic among investors. They have supported as many start-ups as in the US but have seen far from equivalent returns. So what's going on? Science|Business talks to biotechnology consultant John Hodgson.